Study: NCT01803282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: Administered intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: Administered intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: Administered intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: Administered intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: Administered intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: Administered intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: Administered intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: Administered intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: Administered intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: Administered intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: Administered intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: Administered intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered intravenously on Days 1, 8, and 15 of each 28-day treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Administered intravenously on Days 1, 8, and 15 of each 28-day treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered intravenously on Day 1 of each 21-day treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered intravenously on Day 1 of each 21-day treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered intravenously on Day 1 of each 21-day treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Administered intravenously on Days 1 and 15 of each 28-day treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Administered intravenously on Days 1 and 15 of each 28-day treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Administered intravenously on Days 1 and 15 of each 28-day treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Administered intravenously on Days 1 and 15 of each 28-day treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Administered intravenously on Days 1 and 15 of each 28-day treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Administered intravenously on Days 1 and 15 of each 28-day treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Administered intravenously on Days 1 and 15 of each 28-day treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Administered intravenously on Days 1 and 15 of each 28-day treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Administered intravenously on Days 1 and 15 of each 28-day treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Administered intravenously on Days 1 and 15 of each 28-day treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Administered intravenously on Days 1 and 15 of each 28-day treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Administered intravenously on Days 1 and 15 of each 28-day treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Administered intravenously on Days 1 and 15 of each 28-day treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Administered intravenously on Days 1 and 15 of each 28-day treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Administered intravenously on Days 1 and 15 of each 28-day treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Administered intravenously on Days 1 and 15 of each 28-day treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Administered intravenously on Days 1 and 15 of each 28-day treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Administered intravenously on Days 1 and 15 of each 28-day treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Administered intravenously on Days 1 and 15 of each 28-day treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered intravenously on Days 1, 8 and 15 of each 28-day treatment cycle (Breast cancer) or on Day 1 of each 21-day treatment cycle (NSCLC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered intravenously on Days 1, 8 and 15 of each 28-day treatment cycle (Breast cancer) or on Day 1 of each 21-day treatment cycle (NSCLC)